Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

Abstract Background Many migraine patients do not respond adequately to conventional preventive treatments and are therefore described as treatment/medically resistant or difficult to treat cases. Calcitonin gene-related peptide monoclonal antibodies are a relatively novel molecular treatment for ep...

Full description

Bibliographic Details
Main Authors: Emma Troy, Arif A. Shrukalla, Alina Buture, Katie Conaty, Esther Macken, Roisin Lonergan, Jane Melling, Niamh Long, Eamonn Shaikh, Kieran Birrane, Esther M. Tomkins, Peter J. Goadsby, Martin H. Ruttledge
Format: Article
Language:English
Published: BMC 2023-01-01
Series:The Journal of Headache and Pain
Subjects:
Resistant chronic migraine
Erenumab
Patient related outcome measures (PROM)
Headache impact Test-6 (HIT-6)
Migraine associated disability assessment (MIDAS) test
Migraine-specific quality-of-life questionnaire (MSQ)
Online Access:https://doi.org/10.1186/s10194-022-01536-3

Internet

https://doi.org/10.1186/s10194-022-01536-3

Similar Items